CI's Unit Unveils Offering to Expand Access to GLP-1 Medications

Cigna's Evernorth unit has launched a new pharmacy benefit offering aimed at improving access to GLP-1 weight loss medications like WEGOVY and ZEPBOUND by capping monthly copays at $200 or less for patients. This initiative is projected to save patients up to $3,600 annually and reduce net prescription costs for health plan sponsors, potentially boosting Evernorth's revenue, which contributed 82% to Cigna's adjusted revenues in Q1 2025; Cigna's shares have gained 13.3% year-to-date.

Analysis

Edernorth, The Cigna Group's (CI) health services arm, has launched a significant pharmacy benefit offering to improve access and affordability for GLP-1 weight loss medications such as WEGOVY and ZEPBOUND. This initiative caps patient monthly copays at $200 or less, potentially yielding annual savings up to $3,600, and integrates these copayments into annual deductibles, while also streamlining prior authorizations and providing enhanced clinical support through Express Scripts and EnGuide Pharmacy. For health plan sponsors, the offering aims to reduce the net cost per GLP-1 prescription, aligning with Evernorth's strategy to deliver cost savings and improved health outcomes. This new product enhances Evernorth's existing GLP-1 solution suite, which includes the EncircleRx financial model that has already delivered $200 million in savings to health plans since its 2024 inception and covers over 9 million lives. Given that Evernorth contributed 82% to Cigna's overall adjusted revenues in the first quarter of 2025, the anticipated increased utilization of these solutions is poised to drive further revenue growth for this key segment and consequently for Cigna. This strategic move is supported by Cigna's strong year-to-date share price performance of a 13.3% gain, contrasting sharply with the industry's 30% decline, and its current Zacks Rank #2 (Buy) status, further reinforced by a 'strongly positive' overall article sentiment and a CI-specific sentiment score of 0.8.

Key Decisions for Investors

• Investors should view Evernorth's new GLP-1 offering as a positive catalyst for Cigna, given its potential to enhance revenue in a high-growth market and solidify its competitive positioning within pharmacy benefit management.
• The substantial contribution of Evernorth to Cigna's overall revenue, reported at 82% of adjusted revenues in Q1 2025, underscores the strategic importance of this initiative; its successful execution could further support CI's share price outperformance observed year-to-date.
• It is advisable to monitor the market adoption rate of this new GLP-1 benefit, its quantifiable impact on Evernorth's segment revenues in upcoming Cigna quarterly reports, and any evolving competitive dynamics within the GLP-1 medication management space.